Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol

Aldo N Serafini, S. Topchik, H. Jimenez, A. Friden, W. I. Ganz, George N Sfakianakis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To examine the advantages of a 99mTc-labeled cardiac perfusion agent, teboroxime or SQ30,217 (Squibb Diagnostics), a prospective study was undertaken comparing it to 201Tl stress testing in 17 patients suspected or known of having coronary artery disease (CAD). All patients were studied utilizing a single-detector SPECT camera with a continuous acquisition imaging protocol. Testing was performed on a treadmill to comparable levels with both agents within a 2-wk period. Concordance between the two studies on a patient by patient basis was seen in 16/17 (94%) patients, and discordance was seen in 1/17 (6%) patients. Comparison of findings between 201Tl and 99mTc-teboroxime on a segment by segment basis showed concordance in 107/119 (90%) segments, and 12/119 (10%) were discordant. Both examinations independently detected an equal number of normal (77) and abnormal (42) segments. There was no significant difference between the two agents in classifying lesions as ischemic, although there were significant differences between thallium and teboroxime in classifying infarct and infarct/ischemia. Technetium-99m-teboroxime SPECT imaging is a clinically useful method for detecting CAD, with a major advantage being the shorter examination time per individual patient study. The mean total examination time for completion of the 99mTc-teboroxime study was 2.5 hr versus 4.0 hr for 201Tl.

Original languageEnglish
Pages (from-to)1304-1311
Number of pages8
JournalJournal of Nuclear Medicine
Volume33
Issue number7
StatePublished - Jan 1 1992

Fingerprint

Thallium
Technetium
Single-Photon Emission-Computed Tomography
Coronary Artery Disease
technetium Tc 99m teboroxime
Ischemia
Perfusion
Prospective Studies

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Serafini, A. N., Topchik, S., Jimenez, H., Friden, A., Ganz, W. I., & Sfakianakis, G. N. (1992). Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol. Journal of Nuclear Medicine, 33(7), 1304-1311.

Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol. / Serafini, Aldo N; Topchik, S.; Jimenez, H.; Friden, A.; Ganz, W. I.; Sfakianakis, George N.

In: Journal of Nuclear Medicine, Vol. 33, No. 7, 01.01.1992, p. 1304-1311.

Research output: Contribution to journalArticle

Serafini, AN, Topchik, S, Jimenez, H, Friden, A, Ganz, WI & Sfakianakis, GN 1992, 'Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol', Journal of Nuclear Medicine, vol. 33, no. 7, pp. 1304-1311.
Serafini, Aldo N ; Topchik, S. ; Jimenez, H. ; Friden, A. ; Ganz, W. I. ; Sfakianakis, George N. / Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol. In: Journal of Nuclear Medicine. 1992 ; Vol. 33, No. 7. pp. 1304-1311.
@article{ddd33db2cead4d419f0e3652d3ca0864,
title = "Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol",
abstract = "To examine the advantages of a 99mTc-labeled cardiac perfusion agent, teboroxime or SQ30,217 (Squibb Diagnostics), a prospective study was undertaken comparing it to 201Tl stress testing in 17 patients suspected or known of having coronary artery disease (CAD). All patients were studied utilizing a single-detector SPECT camera with a continuous acquisition imaging protocol. Testing was performed on a treadmill to comparable levels with both agents within a 2-wk period. Concordance between the two studies on a patient by patient basis was seen in 16/17 (94{\%}) patients, and discordance was seen in 1/17 (6{\%}) patients. Comparison of findings between 201Tl and 99mTc-teboroxime on a segment by segment basis showed concordance in 107/119 (90{\%}) segments, and 12/119 (10{\%}) were discordant. Both examinations independently detected an equal number of normal (77) and abnormal (42) segments. There was no significant difference between the two agents in classifying lesions as ischemic, although there were significant differences between thallium and teboroxime in classifying infarct and infarct/ischemia. Technetium-99m-teboroxime SPECT imaging is a clinically useful method for detecting CAD, with a major advantage being the shorter examination time per individual patient study. The mean total examination time for completion of the 99mTc-teboroxime study was 2.5 hr versus 4.0 hr for 201Tl.",
author = "Serafini, {Aldo N} and S. Topchik and H. Jimenez and A. Friden and Ganz, {W. I.} and Sfakianakis, {George N}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "1304--1311",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Clinical comparison of technetium-99m-teboroxime and thallium-201 utilizing a continuous SPECT imaging protocol

AU - Serafini, Aldo N

AU - Topchik, S.

AU - Jimenez, H.

AU - Friden, A.

AU - Ganz, W. I.

AU - Sfakianakis, George N

PY - 1992/1/1

Y1 - 1992/1/1

N2 - To examine the advantages of a 99mTc-labeled cardiac perfusion agent, teboroxime or SQ30,217 (Squibb Diagnostics), a prospective study was undertaken comparing it to 201Tl stress testing in 17 patients suspected or known of having coronary artery disease (CAD). All patients were studied utilizing a single-detector SPECT camera with a continuous acquisition imaging protocol. Testing was performed on a treadmill to comparable levels with both agents within a 2-wk period. Concordance between the two studies on a patient by patient basis was seen in 16/17 (94%) patients, and discordance was seen in 1/17 (6%) patients. Comparison of findings between 201Tl and 99mTc-teboroxime on a segment by segment basis showed concordance in 107/119 (90%) segments, and 12/119 (10%) were discordant. Both examinations independently detected an equal number of normal (77) and abnormal (42) segments. There was no significant difference between the two agents in classifying lesions as ischemic, although there were significant differences between thallium and teboroxime in classifying infarct and infarct/ischemia. Technetium-99m-teboroxime SPECT imaging is a clinically useful method for detecting CAD, with a major advantage being the shorter examination time per individual patient study. The mean total examination time for completion of the 99mTc-teboroxime study was 2.5 hr versus 4.0 hr for 201Tl.

AB - To examine the advantages of a 99mTc-labeled cardiac perfusion agent, teboroxime or SQ30,217 (Squibb Diagnostics), a prospective study was undertaken comparing it to 201Tl stress testing in 17 patients suspected or known of having coronary artery disease (CAD). All patients were studied utilizing a single-detector SPECT camera with a continuous acquisition imaging protocol. Testing was performed on a treadmill to comparable levels with both agents within a 2-wk period. Concordance between the two studies on a patient by patient basis was seen in 16/17 (94%) patients, and discordance was seen in 1/17 (6%) patients. Comparison of findings between 201Tl and 99mTc-teboroxime on a segment by segment basis showed concordance in 107/119 (90%) segments, and 12/119 (10%) were discordant. Both examinations independently detected an equal number of normal (77) and abnormal (42) segments. There was no significant difference between the two agents in classifying lesions as ischemic, although there were significant differences between thallium and teboroxime in classifying infarct and infarct/ischemia. Technetium-99m-teboroxime SPECT imaging is a clinically useful method for detecting CAD, with a major advantage being the shorter examination time per individual patient study. The mean total examination time for completion of the 99mTc-teboroxime study was 2.5 hr versus 4.0 hr for 201Tl.

UR - http://www.scopus.com/inward/record.url?scp=0026684976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026684976&partnerID=8YFLogxK

M3 - Article

C2 - 1613570

AN - SCOPUS:0026684976

VL - 33

SP - 1304

EP - 1311

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -